Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=100079
Samsung Bioepis Holdings to Expand New Drug Development on Biosimilar Success
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
Seo Jin-seok, CEO of Celltrion, Announces Major Expansion of New Drug Development at JPMorgan Healthcare Conference
Celltrion announced at the JPMorgan Healthcare Conference that it will expand its new drug pipeline and U.S. manufacturing, aiming to quadruple its biosimilar portfolio and strengthen its global market position.
Celltrion to Present New Drug Development Achievements and CMO Vision at JP Morgan Conference
Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
Chong Kun Dang Co. has launched Archela Inc., a new drug development subsidiary focused on three innovative pipelines—CETP inhibitor, GLP-1 agonist, and HDAC6 inhibitor—aiming to drive future growth and global expansion.
#YonhapInfomax #ChongKunDang #Archela #NewDrugDevelopment #CETPInhibitor #GLP1Agonist #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=86667
Chong Kun Dang Establishes New Drug Development Subsidiary 'Archela'—Focus on Three Key Pipelines
Chong Kun Dang Co. has launched Archela Inc., a new drug development subsidiary focused on three innovative pipelines—CETP inhibitor, GLP-1 agonist, and HDAC6 inhibitor—aiming to drive future growth and global expansion.
South Korea’s K-Melody Project proposes using national bio data for AI-driven drug development and sharing profits with citizens, aiming to foster innovation and a virtuous cycle in the biotech sector.
#YonhapInfomax #KMelody #BioData #NewDrugDevelopment #ArtificialIntelligence #ProfitSharing #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=67084
Kim Hwa-jong, Head of K-Melody Project – 'Developing New Drugs Using National Bio Data and Sharing Profits with Citizens'
South Korea’s K-Melody Project proposes using national bio data for AI-driven drug development and sharing profits with citizens, aiming to foster innovation and a virtuous cycle in the biotech sector.
Yonhap Infomax News